Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Pfizer

Status: Withdrawn

Conditions: Cholecystitis; Appendicitis; Abscess, Intra-Abdominal; Wound Infections; Peritonitis

Treatments: Drug: CP-75385-02 Cefoperazone/sulbactam

Study type: Observational

Funder types: Industry

Identifiers

NCT00463762

A1891004

Details and patient eligibility

About

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female patient of age 18 years or older.
• Patient with intraabdominal/hepatobiliary infection.?

Exclusion criteria

• Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.